Apollomics Inc Class A Ordinary Shares
Price & Volume
Stats
See more52W Range | $4.71-$49 |
Market Cap | $6.4M |
Shares Short | 2,884 |
Financials
See moreRevenue (12 Mos) | $198,000 |
Revenue Growth (YoY) | 262.3% |
Gross Profit (12 Mos) | $198,000 |
Diluted EPS | -$52.80 |
News
See moreYahoo Finance • 21 days ago
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
Yahoo Finance • 24 days ago
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
Yahoo Finance • last year
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
Yahoo Finance • last year
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
About
CEO | Dr. Guo-Liang Yu Ph.D. |
Address | 989 East Hillsdale Blvd, Foster City, CA, United States, 94404 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 13 |
